Overview of Cancer Control in Armenia and Policy Implications.
Armenia
cancer epidemiology
cancer policy
cancer prevention
cancer risk factors
cancer treatment
developing countries
early detection of cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
09
2021
accepted:
15
12
2021
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
29
1
2022
Statut:
epublish
Résumé
Cancer is the second leading cause of death in Armenia. Over the past two decades, the country has seen a significant rise in cancer morbidity and mortality. This review aims to provide up-to-date info about the state of cancer control in Armenia and identify priority areas of research. The paper analyzes published literature and local and international statistical reports on Armenia and similar countries to put numbers into context. While cancer detection, diagnosis, and treatment are improving, the prevalence of risk factors is still quite high and smoking is widespread. Early detection rates are low and several important screening programs are absent. Diagnosis and treatment methods are not standardized; there is a lack of treatment accessibility due to insufficient government coverage and limited availability of essential medicines. Overall, there is room for improvement in this sector, as research is limited and multidisciplinary approaches to the topic are rare.
Identifiants
pubmed: 35087754
doi: 10.3389/fonc.2021.782581
pmc: PMC8787108
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
782581Informations de copyright
Copyright © 2022 Bedirian, Aghabekyan, Mesrobian, Shekherdimian, Zohrabyan, Safaryan, Sargsyan, Avagyan, Harutyunyan, Voskanyan, Tadevosyan, Melik-Nubaryan, Khachatryan, Saghatelyan, Kostanyan, Vardevanyan, Hovhannisyan, Sarkisian, Sargsyan, Babikyan, Tananyan, Danielyan, Muradyan, Tamamyan and Bardakhchyan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Blood Cancer. 2013 May;60(5):889-91
pubmed: 23450774
Proc Nutr Soc. 2008 May;67(2):128-45
pubmed: 18412987
Hematol Oncol Stem Cell Ther. 2020 May 26;:
pubmed: 32533930
BMJ Open. 2015 Sep 24;5(9):e008705
pubmed: 26408285
J Glob Oncol. 2018 Sep;4:1-12
pubmed: 30241241
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):991-994
pubmed: 31030465
Cancers (Basel). 2018 Apr 12;10(4):
pubmed: 29649115